C12Y 107/02
Oxidoreductases acting on other nitrogenous compounds as donors: with a cytochrome as
Official title: with a cytochrome as acceptor (1.7.2)
C12Y107/02 (Oxidoreductases acting on other nitrogenous compounds as donors: with a cytochrome as) appears on 10 US grants and 23 published applications in this corpus.
Search patents in C12Y- Granted patents
- 10
- Published applications
- 23
- Assignees
- 13
- Inventors
- 33
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 2 |
| 2017 | 2 | 0 |
| 2018 | 1 | 2 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 3 |
| 2023 | 0 | 3 |
| 2024 | 1 | 2 |
| 2025 | 0 | 4 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Microbial respiration of chloroxyanions as a source of oxygen for bioprocessing12 May 2026US 12,624,360 B2The Regents of the University of California
- Recombinant microorganism including genetic modification that increases activity of nitric oxide reductase and method of reducing concentration of nitric oxide in sample by using the same10 Feb 2026US 12,545,932 B2Samsung Electronics Co., Ltd.
- Recombinant microorganism including genetic modification that increases activity of nitrous oxide reductase pathway and method of reducing concentration of nitrous oxide in sample by using the same2 Jul 2024US 12,024,710 B2Samsung Electronics Co., Ltd.
- Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof10 May 2022US 11,326,166 B1Alnylam Pharmaceuticals, Inc.
- Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system9 Jul 2019US 10,342,822 B2Board of Regents, The University of Texas System
- Microbial Respiration of Chloroxyanions as a Source of Oxygen for Bioprocessing13 Aug 2026US 2026/0234642 A1The Regents of the University of California
- Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system9 Oct 2025US 2025/0312373 A1Board of Regents, The University of Texas System
- Paracoccus aminovorans bm109 strain and uses thereof12 Jun 2025US 2025/0186511 A1Biome Inc.
- Recombinant microorganism having enhanced ability to remove nitric oxide and use thereof24 Apr 2025US 2025/0129392 A1Samsung Electronics Co., Ltd.
- Recombinant microorganism having enhanced nitrogen oxide reduction ability including genetic modification increasing expression of electron-transfer protein gene, and use thereof6 Feb 2025US 2025/0041800 A1Samsung Electronics Co., Ltd.
Most cited
By later US patents
- Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof2US 11,326,166 B1Alnylam Pharmaceuticals, Inc. · 2022
- Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system2US 9,241,999 B2Board of Regents, The University of Texas System · 2016
- Recombinant microorganism including genetic modification that increases activity of nitrous oxide reductase pathway and method of reducing concentration of nitrous oxide in sample by using the same1US 12,024,710 B2Samsung Electronics Co., Ltd. · 2024